Search Everything in One Place

Explore the web, images, videos, news, and more – all in one place.

Finance

3M analysts increase their forecasts after strong Q2 earnings

3M logo on building
3M logo on building

3M Company MMM on Tuesday reported better-than-expected second-quarter results and raised its full-year guidance. The company posted adjusted earnings of $2.40 per share, beating the analyst consensus estimate of $2.25. Revenue rose 2.4% year over year to $6.50 billion, topping expectations of $6.41 billion. 3M increased its 2026 adjusted earnings forecast to a range of $8.80 to $8.95 per share from its prior outlook of $8.50 to $8.70. The new...

3M Company MMM on Tuesday reported better-than-expected second-quarter results and raised its full-year guidance.

The company posted adjusted earnings of $2.40 per share, beating the analyst consensus estimate of $2.25. Revenue rose 2.4% year over year to $6.50 billion, topping expectations of $6.41 billion.

3M increased its 2026 adjusted earnings forecast to a range of $8.80 to $8.95 per share from its prior outlook of $8.50 to $8.70. The new range is above the Wall Street consensus estimate of $8.75.

The company also updated its full-year revenue outlook to a range of $23.19 billion to $25.37 billion, compared with analysts’ estimate of $25.15 billion.

“We delivered a strong second quarter, exceeding expectations with mid-single-digit sales growth, robust operating margins of about 25%, and double-digit EPS growth, reflecting the progress we’re making on our strategic priorities and building a higher-performing company,” said William Brown, 3M Chairman and CEO. “As a result of our strong first-half performance and continued momentum, we are increasing our full-year guidance and remain confident in our ability to create long-term value for shareholders. I want to thank the 3M team for their disciplined execution, dedication, and relentless focus on delivering innovative solutions for our customers.”

3M shares fell 2.5% to trade at $168.72 on Wednesday.

These analysts made changes to their price targets on 3M following earnings announcement.

  • RBC Capital analyst Deane Dray maintained the stock with an Underperform rating and raised the price target from $123 to $132.
  • Citigroup analyst Andrew Kaplowitz maintained the stock with a Neutral and raised the price target from $166 to $183.

Considering buying MMM stock? Here’s what analysts think:

3M Analysts Increase Their Forecasts After Strong Q2 Earnings

Photo via Shutterstock

SPONSORED

Retirement can be a difficult part of life to navigate, and a financial advisor can help. Finding a qualified financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you're ready to find an advisor who can help you achieve your financial goals, get started now.

This article 3M Analysts Increase Their Forecasts After Strong Q2 Earnings originally appeared on Benzinga.com.

Read full story on Benzinga

Related News

More stories you might be interested in.

Meta AI splurge puts monetization gap in focus ahead of Q2 earnings: Wedbush
Benzinga·1 hour ago

Meta AI splurge puts monetization gap in focus ahead of Q2 earnings: Wedbush

Meta Platforms Inc. META heads into its second-quarter earnings report next week under pressure, with shares slipping Wednesday as investors weighed persistent concerns over the company’s heavy AI spending despite Wall Street expecting another quarter of strong growth. Wedbush Securities analysts Ygal Arounian and Chase Tohanczyn maintained a Neutral rating and a 12-month price forecast of $671 on the stock. Meta has a consensus price forecast...

Why Dr. Reddy's sank: Profit plunge, semaglutide setback and Trump's tariff threat
Benzinga·1 hour ago

Why Dr. Reddy's sank: Profit plunge, semaglutide setback and Trump's tariff threat

Dr. Reddy’s Laboratories Ltd. RDY stock fell Wednesday after the generic drugmaker reported first-quarter fiscal 2027 earnings and revenue that missed Wall Street estimates. Investors also weighed U.S. President Donald Trump’s plan to impose steep tariffs on imported generic drugs over the next several years. Trump Details Phased Generic Drug Tariff Plan Trump said generic drugs imported into the U.S. would remain exempt from tariffs until...

GE Vernova says it's 'mostly sold out' through 2030
Benzinga·1 hour ago

GE Vernova says it's 'mostly sold out' through 2030

Artificial intelligence has fueled a surge in demand for power infrastructure, but GE Vernova Inc. GEV says investors may still be underestimating just how far into the future that demand now stretches. Speaking on the company’s second-quarter earnings call Wednesday, CEO Scott Strazik said GE Vernova expects to finish the year with at least 125 gigawatts of gas turbines under contract—enough to leave the company “mostly sold out through ’30”...

AirJoule jumps as Kubota partnership signals near-term commercial potential
Benzinga·1 hour ago

AirJoule jumps as Kubota partnership signals near-term commercial potential

AirJoule Technologies Corporation AIRJ shares surged on Wednesday after the climate-tech company announced a commercial partnership with Kubota Corporation KUBTY. The surge reflects strong market interest in the deal’s near-term revenue potential, which includes an initial purchase of two systems, exclusive distribution rights in key Sunbelt states, and a path to a broader national rollout. Initial Deployments Kubota will exclusively market,...

Top